Opioid Receptors Influence Ischemia-Reperfusion Injury
|ClinicalTrials.gov Identifier: NCT00184938|
Recruitment Status : Suspended
First Posted : September 16, 2005
Last Update Posted : March 28, 2008
The most powerful protective mechanism against ischemia-reperfusion injury other than rapid reperfusion is ischemic preconditioning. Ischemic preconditioning is defined as the development of tolerance to ischemia-reperfusion injury by a previous short bout of ischemia resulting in a marked reduction in infarct size. This mechanism can be mimicked by several pharmacological substances such as adenosine and morphine.
We, the researchers at Radboud University Nijmegen Medical Centre, have recently developed a method in which we can detect ischemia-reperfusion injury in the human forearm by using Annexin A5 scintigraphy (Rongen et al). With this method we will determine whether opioid receptors are involved in ischemic preconditioning. We expect to find that morphine can mimic ischemic preconditioning and that acute ischemic preconditioning can be blocked with the opioid receptor antagonist naloxon. This study will increase our knowledge about the mechanism of ischemic preconditioning and may also provide leads to exploit this endogenous protective mechanism in a clinical setting.
|Condition or disease||Intervention/treatment||Phase|
|Ischemia-Reperfusion Injury||Drug: morphine Drug: naloxone Drug: Technetium-TC99m-labeled Annexin A5 Procedure: forearm ischemic exercise Procedure: ten minute forearm ischemia||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Opioid Induced Acute Preconditioning|
|Study Start Date :||January 2005|
- Percentual difference in Annexin A5 targetting between the experimental and control arm 1 and 4 hours after intravenous injection
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00184938
|Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology|
|Nijmegen, Gelderland, Netherlands, 6500 HB|
|Principal Investigator:||Gerard Rongen, MD, Phd||Radboud University Nijmegen Medical Centre / Department of Pharmacology and Toxicology|